Results 21 to 30 of about 14,325 (202)

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE

Кардиоваскулярная терапия и профилактика, 2015
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj   +1 more source

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. [PDF]

PLoS ONE, 2011
Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD).
Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper   +4 more
doaj   +1 more source

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury

Frontiers in Pharmacology, 2021
The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In two
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Mark Bush, Vincent Benn, Y. Fred Yang, Jay Zhang   +8 more
doaj   +1 more source

Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

, 2016
BACKGROUND AND OBJECTIVES: Sudden cardiac death (SCD) is a severe burden of modern medicine. Aldosterone antagonist is publicized as effective in reducing mortality in patients with heart failure (HF) or post myocardial infarction (MI).
Al-Gobari, M., Bejan-Angoulvant, T., Cucherat, M., El-Khatib, C., Fall, M., Gueyffier, F., Guitarian, F., Janiaud, P., Le, H.H., Marchant, I., Mombled, M.   +10 more
core   +13 more sources

Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division

Frontiers in Endocrinology, 2020
Introduction: Mineralocorticoid receptor (MR) activation within adipose tissue, triggers inflammation and metabolic syndrome development. The pharmacological blockade of MR provides beneficial effects for adipose tissue. Our study evaluates the impact of
Andrea Vecchiola, Andrea Vecchiola, Cristóbal A. Fuentes, Isidora Solar, Carlos F. Lagos, Maria Cecilia Opazo, Maria Cecilia Opazo, Natalia Muñoz-Durango, Natalia Muñoz-Durango, Claudia A. Riedel, Claudia A. Riedel, Gareth I. Owen, Gareth I. Owen, Alexis M. Kalergis, Alexis M. Kalergis, Alexis M. Kalergis, Carlos E. Fardella, Carlos E. Fardella, Carlos E. Fardella   +18 more
doaj   +1 more source

Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain [PDF]

, 2013
We demonstrated a role for the Mg2 + transporter TRPM7, a bifunctional protein with channel and α-kinase domains, in aldosterone signaling. Molecular mechanisms underlying this are elusive.
Yogi, A., Callera, G.E., O'Connor, S., Antunes, T.T., Valinsky, W., Miquel, P., Montezano, A.C.I., Perraud, A.-L., Schmitz, C., Shrier, A., Touyz, R.M.   +10 more
core   +2 more sources

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial [PDF]

, 2016
Introduction: Diabetes mellitus affects 9% of the European population and accounts for 15% of healthcare expenditure, in particular, due to excess costs related to complications.
Beige, Joachim, Currie, Gemma, Delles, Christian, Lindhardt, Morten, Mischak, Harald, Navis, Gerjan, Noutsou, Marina, Ortiz, Alberto, Persson, Frederik, Pontillo, Claudia, Rossing, Peter, Ruggenenti, Piero Luigi, Rychlik, Ivan, Spasovski, Goce, von der Leyen, Heiko   +14 more
core   +4 more sources

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

Frontiers in Pharmacology, 2013
The mineralocorticoid receptor (MR) antagonists PF 03882845 and eplerenone were evaluated for renal protection against aldosterone mediated renal disease in uninephrectomized Sprague Dawley (SD) rats maintained on a high salt diet and receiving ...
Stephen eOrena, Stephen eOrena, Tristan eMaurer, Rena eEudy, Rena eEudy, Li eShe, Darla eDash, Paula eLoria, Mary Ellen eBanker, Vincent eBernardo, Meera eTugnait, Carlin eOkerberg, Jessie eQian, Carine M Boustany-Kari, Carine M Boustany-Kari   +14 more
doaj   +1 more source

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy

Case Reports in Ophthalmology, 2015
Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating ...
Kapil G. Kapoor, Alan L. Wagner
doaj   +1 more source